AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19191674
Drug: T80/H25 fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T80/H25 fixed-dose combination (FDC) with additional antihypertensive medication
Trial: 9296409
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml 0.17% bupivacaine in 2.66% dextrose without fentanyl (Group I)
Trial: 9296409
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml 0.17% bupivacaine in 2.66% dextrose with 10 microg fentanyl (Group II)
Trial: 27642130
Drug: GEN-003 vaccine
RxNorm normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEN-003 vaccine
Trial: 23392542
Drug: B6 (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B6 (250 mg/day) for five months
Trial: 23392542
Drug: B1+B6 (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B1+B6 (250 mg/day each) for five months
Trial: 9164897
Drug: sustained-release verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sustained-release verapamil
Trial: 7695185
Drug: Combined drug
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined drug therapy to prevent restenosis
Trial: 7695185
Drug: Local delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local delivery of drug at the site of injury
Trial: 7695185
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of highly specific drugs including local gene therapy
Trial: 2687007
Drug: Miglitol 50
RxNorm normalized name: miglitol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglitol 50 mg
Trial: 2687007
Drug: Miglitol 100
RxNorm normalized name: miglitol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglitol 100 mg
Trial: 2687007
Drug: Miglitol 75
RxNorm normalized name: Miglitol
DrugBank: Miglitol (DB00491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Miglitol 75 mg
Trial: 2687007
Drug: Miglitol 200
RxNorm normalized name: Miglitol
DrugBank: Miglitol (DB00491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Miglitol 200 mg
Trial: 363071
Drug: Butacote (enteric-coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butacote (enteric-coated phenylbutazone) 300 mg daily
Trial: 31030296
Drug: N-acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl cysteine (NAC; 20 mg/kg)
Trial: 23517509
Drug: Implant with
RxNorm normalized name: ocular implant with insertion tool for ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant with dual acid-etched surface and CaP nanoparticles
Trial: 23517509
Drug: Control implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control implant with dual acid-etched surface
Trial: 10870784
Drug: Continue exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue exercise (5 or more times weekly)
Trial: 10870784
Drug: Reduce exercise
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduce exercise (to 3 or fewer sessions of exercise weekly)
Trial: 9234649
Drug: Yohimbine 5.4
RxNorm normalized name: yohimbine 5.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine 5.4 mg t.i.d.
Trial: 9234649
Drug: Yohimbine 10.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine 10.8 mg t.i.d.
Trial: 9234649
Drug: Yohimbine 16.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine 16.2 mg t.i.d.
Trial: 9234649
Drug: Yohimbine 21.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine 21.6 mg b.i.d.
Trial: 23161001
Drug: Yohimbine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (all doses)
Trial: 8129993
Drug: Cyclic mebendazole
RxNorm normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyclic mebendazole therapy
Trial: 8129993
Drug: Continuous mebendazole
RxNorm normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous mebendazole therapy
Trial: 25156886
Drug: APV (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APV (weekly vinblastine)
Trial: 23364472
Drug: 17DD yellow
RxNorm normalized name: YELLOW 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17DD yellow fever vaccine (17DD‐YFV) at doses from 27,476 IU to 31 IU
Trial: 12678140
Drug: Bitter melon
RxNorm normalized name: BITTER MELON
DrugBank: Momordica charantia fruit (DB14265)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bitter melon ingestion (patient treatment group)
Trial: 10781759
Drug: Extended-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin 375 mg/day to 3,000 mg/day
Trial: 10781759
Drug: Extended-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin 1,000 mg/day to 3,000 mg/day
Trial: 8641928
Drug: G‐CSF administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF administered as required (single injections, n = 21)
Trial: 8641928
Drug: G‐CSF administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF administered for at least 3 consecutive days (n = 20)
Trial: 8641928
Drug: G‐CSF (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (both groups)
Trial: 29767802
Drug: START-Play intervention
RxNorm normalized name: Star Anise Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: START-Play intervention (individualized twice-weekly home intervention for 12 weeks)
Trial: 24549105
Drug: Risperidone or
RxNorm normalized name: risperidone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone or aripiprazole (antipsychotic treatment) for 12 weeks
Trial: 11028837
Drug: Oral tropisetron
RxNorm normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tropisetron (5 mg once daily) for 15 days
Trial: 11028837
Drug: Oral ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ondansetron (2 x 8 mg daily) for 15 days
Trial: 8861177
Drug: Venlafaxine 37.5
RxNorm normalized name: venlafaxine 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 37.5 mg twice daily
Trial: 8861177
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg once daily
Trial: 8861177
Drug: Venlafaxine (increased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (increased to 75 mg twice daily after 2 weeks if inadequate response)
Trial: 6348585
Drug: Pergolide (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pergolide (mean daily dose 3.3 mg, range 0.7 to 7.2 mg)
Trial: 6348585
Drug: Bromocriptine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (mean daily dose 42.7 mg, range 5.8 to 87.5 mg)
Trial: 30144034
Drug: Bilateral Greater
RxNorm normalized name: greater celandine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral Greater Occipital Nerve Block (GONB) with 6 mL of 0.5% bupivacaine
Trial: 30144034
Drug: Sham injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection with 1 mL of 0.5% bupivacaine
Trial: 25317545
Drug: Butorphanol 0.015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol 0.015 mg/kg
Trial: 27367987
Drug: Butorphanol 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol 0.03 mg/kg
Trial: 21480777
Drug: Immediately loaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately loaded implants (40 patients, minimal insertion torque 30 Ncm) with nonoccluding temporary restorations.
Trial: 21480777
Drug: Early loaded
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early loaded implants (40 patients) with definitive restoration after 2 months.
Trial: 12150267
Drug: Traditional therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional therapies appropriate for the patient
Trial: 12150267
Drug: Therapies appropriate
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapies appropriate for the patient with an oral vertical exercise device
Trial: 12150267
Drug: Home care
RxNorm normalized name: Alpha Dent Home Care 0.4% Fluoride Treatment Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home care education and use of the oral exercise device
Trial: 9797793
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg lovastatin after 120 mg diltiazem twice a day for 2 weeks
Trial: 9797793
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg pravastatin after 120 mg diltiazem twice a day for 2 weeks
Trial: 8109598
Drug: r-HuEPO administration
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-HuEPO administration
Trial: 28882919
Drug: THC:CBD oromucosal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC:CBD oromucosal spray (Sativex)
Trial: 23578552
Drug: Glatiramer acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate (GA), daily administration, dosage not specified, duration of therapy not specified.
Trial: 18165591
Drug: IP meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IP meperidine 50 mg
Trial: 18165591
Drug: IP meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IP meperidine 100 mg
Trial: 18165591
Drug: IP ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IP ropivacaine 150 mg
Trial: 18165591
Drug: IP meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IP meperidine 50 mg and ropivacaine 150 mg
Trial: 18165591
Drug: Control (IP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (IP saline with IM meperidine 50 mg)
Trial: 16517311
Drug: Posterior approach
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior approach injection of bupivacaine, methylprednisolone, and gadolinium-DTPA
Trial: 16517311
Drug: Anteromedial approach
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anteromedial approach injection of bupivacaine, methylprednisolone, and gadolinium-DTPA
Trial: 14626567
Drug: Pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg + Fenofibrate 200 mg (n = 46)
Trial: 14626567
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg + Ciprofibrate 100 mg (n = 40)
Trial: 8417220
Drug: Lidocaine-prilocaine cream
RxNorm normalized name: lidocaine / prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine-prilocaine cream (group 1)
Trial: 2874366
Drug: Nasal sprays
RxNorm normalized name: SODIUM CHLORIDE 9 mg in 100 mL INTRASINAL AEROSOL, SPRAY [Cleanote Saline Nasal Sprays]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal sprays of dexamethasone, tramazoline, and neomycin
Trial: 2874366
Drug: Nasal sprays
RxNorm normalized name: SODIUM CHLORIDE 9 mg in 100 mL INTRASINAL AEROSOL, SPRAY [Cleanote Saline Nasal Sprays]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal sprays of dexamethasone and tramazoline with no antibiotic
Trial: 24801842
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (18 mg, 27 IU) and Vitamin E acetate (27 mg, 27 IU) delivered via tube-feeding
Trial: 24801842
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (18 mg, 27 IU) and Vitamin E acetate (27 mg, 27 IU)
Trial: 24801842
Drug: Cubic phase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cubic phase formulation
Trial: 20133508
Drug: Subcutaneous golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous golimumab 50 mg
Trial: 20133508
Drug: Subcutaneous golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous golimumab 100 mg
Trial: 20133508
Drug: Subcutaneous golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous golimumab (both doses)
Trial: 16435076
Drug: Bisphosphonate therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphonate therapy (10 mg alendronate or 5 mg risedronate) with calcium/vitamin D
Trial: 16435076
Drug: Calcium/vitamin D
RxNorm normalized name: CALCIUM/VITAMIN D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium/vitamin D treatment alone (control group)
Trial: 14984232
Drug: Prednisone (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (60 mg/day for 2 days, 40 mg/day for 2 days, and 20 mg/day for 2 days) for 6 days
Trial: 14984232
Drug: Naratriptan (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naratriptan (2.5 mg twice a day) during the initial period
Trial: 14984232
Drug: Nothing (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nothing (no regular medications) during the initial period
Trial: 10858975
Drug: Valsartan 80
RxNorm normalized name: valsartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 80 mg orally for 14 to 21 days
Trial: 30053843
Drug: Adherence Rating
RxNorm normalized name: Aratinga erythrogenys feather extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence Rating Scale (ARS) based on exercise therapy adherence prediction model.
Trial: 24912491
Drug: Methylphenidate (intravenous)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (intravenous)
Trial: 14640255
Drug: Lipid lowering
RxNorm normalized name: Lipid lowering agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid lowering treatment
Trial: 7352849
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment beyond short detoxification
Trial: 25967707
Drug: Low-nitrogen and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-nitrogen and low-calorie parenteral nutrition combined with enteral nutrition (EN)
Trial: 22433704
Drug: Ingavirin combined
RxNorm normalized name: Ingavirin
DrugBank: Ingavirin (DB11944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingavirin combined with an antibacterial agent
Trial: 19673928
Drug: Prolonged-release (PR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release (PR) torasemide 5 mg
Trial: 19673928
Drug: Prolonged-release (PR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release (PR) torasemide 10 mg
Trial: 19673928
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) torasemide 5 mg
Trial: 19673928
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) torasemide 10 mg
Trial: 15089807
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg kg(‐1) ephedrine sulphate
Trial: 15089807
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg kg(‐1) ephedrine sulphate
Trial: 15089807
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg kg(‐1) ephedrine sulphate
Trial: 9626213
Drug: Cisplatin 80
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 80 mg/m2 + Teniposide 100 mg/m2 (arm A)
Trial: 9626213
Drug: Paclitaxel 175
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m2 (arm B)
Trial: 7923659
Drug: c7E3 Fab
RxNorm normalized name: aDabi-Fab
DrugBank: Idarucizumab (DB09264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: c7E3 Fab (0.25 mg/kg bolus dose)
Trial: 7923659
Drug: c7E3 Fab
RxNorm normalized name: aDabi-Fab
DrugBank: Idarucizumab (DB09264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: c7E3 Fab (continuous infusion for up to 24 hours)
Trial: 3197915
Drug: Ampicillin suppository
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ampicillin suppository
Trial: 3197915
Drug: Amoxycillin suspension
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin suspension
Trial: 28241991
Drug: Magnesium supplementation
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplementation (two 250‐mg tablets of magnesium oxide daily for 8 weeks)
Trial: 28241991
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two tablets daily for 8 weeks)
Trial: 25727810
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (2000‐4000 IU cholecalciferol) orally daily until delivery
Trial: 19837094
Drug: Cholera vaccine
RxNorm normalized name: Cholera Vaccine
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholera vaccine alone
Trial: 19837094
Drug: Cholera vaccine
RxNorm normalized name: Cholera Vaccine
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholera vaccine plus zinc supplementation
Trial: 19837094
Drug: Cholera vaccine
RxNorm normalized name: Cholera Vaccine
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholera vaccine with zinc supplementation
Trial: 9164520
Drug: Endoscopic Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic Injection Sclerotherapy (EIS)
Trial: 11499184
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol (50 micrograms)
Trial: 11499184
Drug: Intravaginal prostaglandin
RxNorm normalized name: Intravaginal contraceptives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal prostaglandin E2 (4 mg)
Trial: 9571345
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment arm aiming for normal HbA1c levels
Trial: 9571345
Drug: Phase I:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I: evening intermediate or long-acting insulin
Trial: 9571345
Drug: Phase II:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase II: added daytime glipizide (up to 10 mg/day)
Trial: 9571345
Drug: Phase III:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase III: two injections of insulin alone
Trial: 9571345
Drug: Phase IV:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase IV: multiple daily insulin injections
Trial: 9571345
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of glipizide and insulin (up to 20 mg/day)
Trial: 24021517
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (100 μg twice weekly) with cyclic progesterone
Trial: 24021517
Drug: Placebo patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patches and pills
Trial: 18372276
Drug: Warfarin for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin for long-term secondary prevention of VTE
Trial: 12352277
Drug: Antidepressant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant treatment (sertraline, desipramine)
Trial: 8126147
Drug: Acipimox (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (125 mg, 12 times/24 h)
Trial: 2768614
Drug: Client-centered relationship
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Client-centered relationship therapy (RT)
Trial: 27862950
Drug: Transdermal 17β‐oestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17β‐oestradiol (E2) 0.15 mg
Trial: 25819860
Drug: Apixaban 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 5.0 mg twice daily
Trial: 23594968
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg loading dose of prasugrel
Trial: 23594968
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg loading dose of prasugrel
Trial: 23594968
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg maintenance dose of prasugrel
Trial: 23594968
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg maintenance dose of prasugrel
Trial: 23594968
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg maintenance dose of prasugrel
Trial: 23594968
Drug: Daily 5
RxNorm normalized name: Walgreens Gold Seal One Daily 50 Plus Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 5 mg doses of prasugrel
Trial: 23594968
Drug: 10 mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg, 7.5 mg, and 5 mg doses of prasugrel